● Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Condition: Follicular Lymphoma and Marginal Zone Lymphoma · Sponsor: Beijing Mabworks Biotech Co., Ltd.

PhasePhase 1/Phase 2

Planned participants53

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

This description comes directly from the study's public registry record.

Talk to the study team

Yuankai Shi, MD · (+86)010-87788293 · syuankaipumc@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04110301